View in EDS HTML Full Text PDF Full Text

HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial.

Saved in:
Bibliographic Details
Title: HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial.
Authors: Li SH; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China., Zuo ZJ; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China., Lu LH; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China., Xu LZ; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China., Wang QX; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China., Zhao RC; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China., Mei J; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China., Li JB; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Department of Clinical Research Methodology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China., Zheng L; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China., Guo RP; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. guorp@sysucc.org.cn.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China. guorp@sysucc.org.cn., Wei W; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. weiwei@sysucc.org.cn.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China. weiwei@sysucc.org.cn.; Department of Hepatopancreatobiliary Surgery, Gansu Hospital of Sun Yat-sen University Cancer Center, Lanzhou, Gansu, China. weiwei@sysucc.org.cn.
Source: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2026 May 15; Vol. 11 (1). Date of Electronic Publication: 2026 May 15.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42135293
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+SH%22">Li SH</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Zuo+ZJ%22">Zuo ZJ</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Lu+LH%22">Lu LH</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Xu+LZ%22">Xu LZ</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Wang+QX%22">Wang QX</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Zhao+RC%22">Zhao RC</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Mei+J%22">Mei J</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Li+JB%22">Li JB</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Department of Clinical Research Methodology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Zheng+L%22">Zheng L</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Guo+RP%22">Guo RP</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. guorp@sysucc.org.cn.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China. guorp@sysucc.org.cn.<br /><searchLink fieldCode="AU" term="%22Wei+W%22">Wei W</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. weiwei@sysucc.org.cn.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China. weiwei@sysucc.org.cn.; Department of Hepatopancreatobiliary Surgery, Gansu Hospital of Sun Yat-sen University Cancer Center, Lanzhou, Gansu, China. weiwei@sysucc.org.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101676423%22">Signal transduction and targeted therapy</searchLink> [Signal Transduct Target Ther] 2026 May 15; Vol. 11 (1). <i>Date of Electronic Publication: </i>2026 May 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101676423 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-3635 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220593635%22">20593635 </searchLink><i>NLM ISO Abbreviation: </i>Signal Transduct Target Ther <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42135293
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41392-026-02718-0
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li SH
      – PersonEntity:
          Name:
            NameFull: Zuo ZJ
      – PersonEntity:
          Name:
            NameFull: Lu LH
      – PersonEntity:
          Name:
            NameFull: Xu LZ
      – PersonEntity:
          Name:
            NameFull: Wang QX
      – PersonEntity:
          Name:
            NameFull: Zhao RC
      – PersonEntity:
          Name:
            NameFull: Mei J
      – PersonEntity:
          Name:
            NameFull: Li JB
      – PersonEntity:
          Name:
            NameFull: Zheng L
      – PersonEntity:
          Name:
            NameFull: Guo RP
      – PersonEntity:
          Name:
            NameFull: Wei W
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 05
              Text: 2026 May 15
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2059-3635
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Signal transduction and targeted therapy
              Type: main
ResultId 1